Impact of Elexacaftor/Tezacaftor/Ivacaftor on Healthcare Resource Utilization and Associated Costs Among People With Cystic Fibrosis in the US: A Retrospective Claims Analysis

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Healthcare Resource Utilization and Associated Costs Among People With Cystic Fibrosis in the US: A Retrospective Claims Analysis

Abstract Introduction Cystic fibrosis (CF) is a life-limiting genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) is a CFTR modulator (CFTRm) that targets the underlying cause of CF. Based on safet...

Full description

Bibliographic Details
Main Authors: Michael S. Schechter, Natalia Sabater-Anaya, Gerry Oster, Derek Weycker, Hongsheng Wu, Emilio Arteaga-Solis, Sukirti Bagal, Lisa J. McGarry, Kate Van Brunt, Jessica Morlando Geiger
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-10-01
Series:Pulmonary Therapy
Subjects:
CFTR modulator
Claims
Elexacaftor
HCRU
Healthcare cost
Healthcare resource utilization
Online Access:https://doi.org/10.1007/s41030-023-00241-z

Internet

https://doi.org/10.1007/s41030-023-00241-z

Similar Items